Displaying 141 - 160 of 853
Active Ingredient CARBOPLATIN
Therapeutic Class ANTINEOPLASTICS
Indications Advanced ovarian cancers and of small-cell lung cancer.
Caution As for cisplatin. Myelosuppression may be more severe than cisplatin and prolonged in patients with impaired renal function.
Dose Range Adult: dose of carboplatin is determined according to renal function rather than body surface area.
Drug Interactions
Pregnancy Carboplatin can cause fetal toxicity when administered to pregnant women, but po More ...
Breast Feeding Because of the potential for serious adverse reactions to carboplatin in nursing More ...
Active Ingredient CHLORAMBUCIL
Therapeutic Class ANTINEOPLASTICS
Indications Chronic lymphocytic leukemia, lymphomas
Caution Anorexia, nausea, leukop enia, throm-bocytopenia, anaemia. Drink 6-8 glasses of liquid everyday.Avoid aspirin or medication containing aspirin.
Dose Range 0.1-0.2mg/kg/day (usually 4-10mg once daily ) for 3-4 weeks.
Drug Interactions
Pregnancy Chlorambucil can cause fetal harm when administered to pregnant women, but poten More ...
Breast Feeding Discontinue breast-feeding.
Active Ingredient CISPLATIN
Therapeutic Class ANTINEOPLASTICS
Indications Treatment of testicular, lung, cervical, bladder, head and neck, and ovarian cancer.
Caution Alop ecia, bone-marrow suppression,extravasation, hyperuricaemia, hypomagnesaemia, myelosuppression, nephrotoxicity severe nausea, severe vomiting.
Dose Range
Drug Interactions
Pregnancy Cisplatin may cause fetal harm when administered to a pregnant woman but potenti More ...
Breast Feeding Cisplatin is distributed into milk. Nursing should be discontinued to avoid the More ...
Active Ingredient CYCLOPHOSPHAMIDE
Therapeutic Class ANTINEOPLASTICS
Indications Non-Hodgkin’s lymphomas.
Caution High fluid intake will help to prevent haemorrhagic cystitis (3-4 litres/day ). C.f. prescribing in renal disease p. 27.
Dose Range Low-dose: 2-6 mg/kg weekly as a single i.v. dose/ in divided oral doses; moderate-dose:10-15 mg/kg weekly as a single i.v. dose; High-dose: 20-40 mg/kg as a single i.v. dose every 10-20 days, depending on the disease being treated, condi
Drug Interactions
Pregnancy Cyclophosphamide can cause fetal toxicity when administered to pregnant women, b More ...
Breast Feeding Discontinue breast-feeding during and for 36 hours after stopping treatment.
Active Ingredient CYCLOSPORIN
Therapeutic Class ANTINEOPLASTICS
Indications Prophylaxis of graft rejection in Organ and tissue transplantation.
Caution Abdominal pain; anorexia; diarrhoea; fatigue; gingival hyperplasia; headache; hepatic dysfunction. Renal dysfunction (renal structural changes on long-term administration).
Dose Range Ciclosp orin is 10 to 15 mg/kg daily , beginning 4 to 12 hours before
transp lantation, and continued for 1 to 2 weeks. maintenance 2-6 mg/kg daily, reduce dose gradually to maintenance
Drug Interactions
Pregnancy Cyclosporin crosses the placenta; manufacturer advises to avoid unless potential More ...
Breast Feeding Avoid breastfeeding during cyclosporin therapy.
Active Ingredient CYPROTERONE
Therapeutic Class ANTINEOPLASTICS
Indications Advanced prostatic carcinoma.
Caution Impotence, inhibition of spermatogenesis, headache, gynecomastia,
galactorrhea, weight gain, lipid abnormalities, gastrointestinal disturbances and anemia. Several cases of hep ato More ...
Dose Range Palliative treatment: 200- 300 mg daily in 2 or 3 divided doses after meals. S uppression of disease flare: 100 mg twice daily used alone for 5 to 7 day s, then with a gonadorelin analogue for 3 to 4 weeks.
Drug Interactions
Pregnancy Use of cyproterone during pregnancy might carry a risk of feminisation of a male More ...
Breast Feeding
Active Ingredient CYTARABINE
Therapeutic Class ANTINEOPLASTICS
Indications Induction of remission of acute myeloblastic leukaemia.
Caution
Dose Range
Drug Interactions
Pregnancy Cytarabine can cause fetal toxicity when administered to pregnant women, but pot More ...
Breast Feeding Discontinue breast-feeding.
Active Ingredient DACARBAZINE
Therapeutic Class ANTINEOPLASTICS
Indications Metastatic melanoma.
Caution
Dose Range
Drug Interactions
Pregnancy Dacarbazine should be used during pregnancy only when the potential benefits jus More ...
Breast Feeding Discontinue breast-feeding.
Active Ingredient DAUNORUBICIN
Therapeutic Class ANTINEOPLASTICS
Indications Induction of remission of acute leukaemias.
Caution Dose related myelosuppression, cardiotoxicity, alopecia, urine discoloration; extravasation.
Dose Range 40 - 60 mg/m2 on alternate days for a course of up to 3 injections.
Drug Interactions
Pregnancy Daunorubicin may cause fetal harm when administered to a pregnant woman. Animal More ...
Breast Feeding Discontinue breastfeeding.
Active Ingredient DOCETAXEL
Therapeutic Class ANTINEOPLASTICS
Indications Use as neoadjuvent with metastatic breast cancer.
Caution As for Paclitaxel.
Dose Range
Drug Interactions
Pregnancy Docetaxel may cause fetal harm when administered to pregnant women, but potentia More ...
Breast Feeding It is not known whether docetaxel is distributed into milk.
Active Ingredient DOXORUBICIN
Therapeutic Class ANTINEOPLASTICS
Indications Hodgkin's disease, non-Hodgkin's lymphomas, acute leukaemias.
Caution Myelosuppression, reversible, alopecia, nausea, vomiting
Dose Range 60-75mg/M 2 i.v. as a single injection every 3 or 4 weeks; or 1.2-2.4 mg/kg once every 3 weeks.
Drug Interactions
Pregnancy Doxorubicin can cause fetal toxicity when administered to pregnant women, but po More ...
Breast Feeding Not recommended.
Active Ingredient EPIRUBICIN
Therapeutic Class ANTINEOPLASTICS
Indications Acute leukaemias, lymphomas, solid tumours.
Caution Leukopenia, nausea and vomiting, diarrhoea, thrombocytopenia, EKG changes, congestive cardiac failure secondary to a diffuse cardiomyopathy, alopecia. C.f. prescribing in liver disease p. 13.
Dose Range
Drug Interactions
Pregnancy Avoid during pregnancy. Teratogenic effects and embryotoxicity were noted in ani More ...
Breast Feeding It is unknown whether epirubicin is distributed in milk. Breastfeeding is theref More ...
Active Ingredient ETOPOSIDE
Therapeutic Class ANTINEOPLASTICS
Indications Small cell carcinoma of the bronchus, the lymphomas and testicular cancer.
Caution Alopecia; bone-marrow supp ression.
Dose Range Adult: Orally , 120–240 mg/m2 daily for 5 days.
Drug Interactions
Pregnancy Etoposide may cause fetal harm when administered to pregnant women, but potentia More ...
Breast Feeding Unknown. Breastfeeding is not recommended.
Active Ingredient EVEROLIMUS
Therapeutic Class ANTINEOPLASTICS
Indications
Caution
Dose Range
Drug Interactions
Pregnancy
Breast Feeding
Active Ingredient EXEMESTANE
Therapeutic Class ANTINEOPLASTICS
Indications Adjuvant treatment of oestrogen-receptor-positive early breast cancer in postmenop ausal women following 2–3 years of tamoxifen therapy Advanced breast cancer in postmenop ausal women in whom antioe More ...
Caution Abdominal pain; alopecia; anorexia; constipation; depression; dizziness; dyspepsia; fatigue; headache; hot flushes; insomnia; nausea; rash; sweating; vomiting.
Dose Range 25mg once a day after a meal.
Drug Interactions
Pregnancy Avoid during pregnancy.
Breast Feeding Breastfeeding is not recommended during exemestane therapy.
Active Ingredient FILGRASTIM
Therapeutic Class ANTINEOPLASTICS
Indications Prevention of neutropenia in patients receiving myelosup pressive cancer chemotherapy and to reduce the period of neutropenia in patients undergoing bone marrow transplantation
Caution Musculoskeletal pain, dysuria
Dose Range Adjunct to antineoplastic therapy, filgrastim is given in a dose of
5 micrograms/kg daily starting not less than 24 hours after t he last dose of antineop lastic. Bone marrow transp lantation is 10 micrograms/kg daily , adjusted according to response.
Drug Interactions
Pregnancy Use only if potential benefit to mother justifies the risk to the fetus.
Breast Feeding Use with caution for lactating women.
Active Ingredient FLUDARABINE
Therapeutic Class ANTINEOPLASTICS
Indications Initial treatment of advanced B-cell chronic lymphocytic leukaemia (CLL) or after first line treatment in patients with sufficient bone-marrow reserves.
Caution Fludarabine has a potent immunosuppresive effect. Patients treated with fludarabine are more prone to serious bacterial, opportunistic fungal, and viral infections, and prophylactic therapy can be use More ...
Dose Range 40 mg/m2 for 5 days every 28 days, usually given for 6 cycles.

By intravenous injection, or by intravenous infusion.
Drug Interactions
Pregnancy
Breast Feeding
Active Ingredient FLUOROURACIL
Therapeutic Class ANTINEOPLASTICS
Indications Gastrointestinal cancer
Caution Anorexia, nausea and vomiting, stomatitis, diarrhoea, thrombocytopenia, alopecia, dermatitis, skin hyperpigmentation.
Dose Range
Drug Interactions
Pregnancy Fluorouracil may cause fetal harm when administered to pregnant women. Animal st More ...
Breast Feeding Not recommended during fluorouracil therapy.
Active Ingredient FLUTAMIDE
Therapeutic Class ANTINEOPLASTICS
Indications Prostate cancer.
Caution Gynecomastia and galactorrhea are the most frequently reported adverse effects and occur in up to 42% of patients. Other adverse effects include diarrhoea, nausea, vomiting and transient serum More ...
Dose Range 250mg 3 times daily .
Drug Interactions
Pregnancy
Breast Feeding
Active Ingredient GOSERELIN
Therapeutic Class ANTINEOPLASTICS
Indications
Caution
Dose Range
Drug Interactions
Pregnancy
Breast Feeding